26 June 2020 - Abbintio, a biosimilar candidate referencing Avastin (bevacizumab), is Samsung Bioepis’ second oncology biosimilar to be recommended for marketing authorisation by the European Medicines Agency.

Samsung Bioepis today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for Aybintio, a biosimilar candidate referencing Avastin (bevacizumab).

Aybintio has been recommended for approval for the treatment of the same types of cancer as reference bevacizumab in the European Union, including metastatic carcinoma of the colon or rectum, metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, epithelial ovarian, fallopian tube and primary peritoneal cancer and cervical cancer.

Read Samsung Bioepis press release